In addition, as LRRK2 mutation carriers have been the focus of most LRRK2-related epidemiological studies of cancer incidence, an overactive LRRK2 phenotype was presupposed; consequently, to our knowledge, a role for LRRK2 loss in cancer pathogenesis has yet to be considered, including for LUAD. This evidence concerns the gene LRRK2 and cancer.